Clinical trial
Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and…
NCT00083928 · Ångstrom Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00083928 |
|---|---|
| Title | Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels |
| Official title | A Phase 2 Randomized, Double-Blind Trial of the Clinical Activity and Safety of Å6 in Patients With Asymptomatic CA125 Progression of Epithelial Ovarian Cancer After First-Line Chemotherapy |
| Lead sponsor | Ångstrom Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Primary Peritoneal Carcinoma |
| Intervention type | Drug |
| Interventions | Å6 subcutaneous injection |
| Enrollment | 60 |
| Start date | May 1, 2004 |
| Primary completion | Feb 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Jun 7, 2004 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: